Donor Considerations in Fecal Microbiota Transplantation

  • Danielle BarnesEmail author
  • K. T. Park
Pediatric Gastroenterology (S Orenstein, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pediatric Gastroenterology


Purpose of Review

Tremendous acceleration has been made in understanding the gut microbiota in the past decade and, with it, further understanding of the pathologic role of dysbiosis and the use of fecal microbiota transplantation (FMT) as therapy. FMT has been studied in many disease states including the most common indication of Clostridium difficile infection (CDI), though many questions regarding stool donor selection remain.

Recent Findings

Though traditionally, one donor has provided stool for one patient, research is underway to explore many donor selection considerations from the use of pooled donor stool to selection of a high diversity donor. It is well-known that dietary intake shapes the gut microbiota and the potential implications of this on FMT donor selection are being explored.


Though further high-quality research is needed, optimizing the fecal microbiota inoculum holds great promise.


Fecal microbiota transplant Clostridium difficile infection FMT donor Competitive donor 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    NIH HMP Working Group et al. The NIH Human Microbiome Project. Genome Res. 2009;19:2317–23.CrossRefGoogle Scholar
  2. 2.
    Jost L. Partitioning diversity into independent alpha and beta components. Ecology. 2007;88:2427–39.CrossRefPubMedGoogle Scholar
  3. 3.
    Bakken JS et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9:1044–9.Google Scholar
  4. 4.
    Kelly CR et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016. doi: 10.7326/M16-0271.Google Scholar
  5. 5.
    •• Lee CH et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315:142–9. This study represents the largest randomized clinical trial of FMT to date.CrossRefPubMedGoogle Scholar
  6. 6.
    •• van Nood E et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15. This study was the first randomized clinical trial of FMT. Prior to this time, the data on FMT was comprised of observational studies.CrossRefPubMedGoogle Scholar
  7. 7.
    Youngster I et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016;14:134.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Youngster I et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and non-alcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016. doi: 10.1152/ajpgi.00245.2016.PubMedGoogle Scholar
  10. 10.
    Agilli M, Ilga U. A methodological approach to fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2015;60:e36.CrossRefPubMedGoogle Scholar
  11. 11.
    Kronman MP et al. Fecal microbiota transplantation via nasogastric tube for recurrent clostridium difficile infection in pediatric patients. J Pediatr Gastroenterol Nutr. 2015;60:23–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Wonderlick JS, D’Agostino R. Fecal microbiota transplantation via fluoroscopy-guided nasojejunal catheter placement: indications, technique, and the role of radiology. Abdom Radiol (N Y). 2016;41:2020–5.CrossRefGoogle Scholar
  13. 13.
    Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile infection. J Vis Exp (JoVE). 2014. doi: 10.3791/52154.Google Scholar
  14. 14.
    Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–9.PubMedGoogle Scholar
  15. 15.
    Kakihana K et al. Fecal microbiota transplantation for patients with steroid-resistant/dependent acute graft-versus-host disease of the gut. Blood. 2016. doi: 10.1182/blood-2016-05-717652.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Moayyedi P, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149, 102–109.e6.Google Scholar
  17. 17.
    Vrieze A, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913–916.e7.Google Scholar
  18. 18.
    • Bousvaros A, Wang K, Rustgi A, Vender R, Relman D. Current consensus guidance on donor screening and stool testing for FMT; 2013. This guidance is used as the primary reference for pre-donation screening for potential donors.Google Scholar
  19. 19.
    Orenstein R et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;62:596–602.CrossRefGoogle Scholar
  20. 20.
    Paramsothy S et al. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis. 2015;21:1600–6.CrossRefPubMedGoogle Scholar
  21. 21.
    O’Donnell MM et al. Preparation of a standardised faecal slurry for ex-vivo microbiota studies which reduces inter-individual donor bias. J Microbiol Methods. 2016;129:109–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535:56–64.CrossRefPubMedGoogle Scholar
  23. 23.
    De Filippo C et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107:14691–6.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ferrocino I et al. Fecal microbiota in healthy subjects following omnivore, vegetarian and vegan diets: culturable populations and rRNA DGGE profiling. PLoS ONE. 2015;10, e0128669.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Estaki M et al. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. Microbiome. 2016;4:42.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022–3.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2017

Authors and Affiliations

  1. 1.Department of Pediatrics, Division of Gastroenterology, Hepatology, and NutritionNaval Medical Center San DiegoSan DiegoUSA
  2. 2.Department of Pediatrics, Division of Gastroenterology, Hepatology and NutritionStanford Children’s HealthPalo AltoUSA

Personalised recommendations